Tagged with pharmaceuticals

Pharma Eric Ducournau, CEO of Pierre Fabre Dermo-Cosmétique (PFDC), discusses the company’s revolutionary lines of dermatologically tested skincare products and their niche adapted internationalization strategy that is focused on providing the highest-quality skincare products for all consumer and patient needs. The Dermo-Cosmetics division of Pierre Fabre has represented about 55 percent…

Pharma The following chart shows the massive potential in the Dutch pharmaceuticals and healthcare markets; a population of almost 17 million with high per capita GDP where a large percentage of the population have long-term health conditions. Click here to read more articles and interviews from the Netherlands, and to download…

Pharma The following chart shows the relative performance of the Egyptian economy by sector and highlights the importance of healthcare and pharmaceuticals as Egypt’s top performing sector. Click here to read more articles and interviews from Egypt, and to download the latest free pharma report from the country.

Pharma The following chart shows the relative performance of the Egyptian economy by sector and highlights the importance of healthcare and pharmaceuticals as Egypt’s top performing sector. Click here to read more articles and interviews from Egypt, and to download the latest free pharma report from the country.

Pharma The following chart shows the prevalence of HIV and AIDS in South Africa; a country where 6.3 million people are living with HIV and in which there are 200,000 AIDS-related deaths per year. Click here to read more articles and interviews from South Africa, and to download the latest free…

Pharma Doppel has been selected as the nucleus for significant investments in the CDMO industry by PE firm Trilantic Capital Partners, according to recently hired CEO Giuseppe Cassisi, who shares the organization’s plans to invest in both greenfield facilities and M&A in the coming years. Italy’s pharmaceutical exports are growing faster than any other…

Pharma The managing director of Janssen Hungary, Andreas Woitossek, depicts the valuable role of real-world evidence in enabling the affiliate’s consistent double-digit growth over the last four years, while highlighting the advantages of using Hungary as a strategic hub. He also shares his vision for Janssen Academy—an institute set to become…

Pharma Janssen Czech Republic’s MD reviews his longstanding career within the company and highlights how founder Dr. Paul Janssen’s legacy still influences operations today. He also compares the Czech regulatory environment with those of its regional neighbors and finds that there is little ground for fair comparison. You have been with…

Pharma Sergio Liberatore discusses IMS Health Italy’s evolution after the acquisition of Cegedim’s CRM and strategic data businesses and how IMS is paving the way for pharma companies to become more patient-centric. When we last interviewed you in 2009, you were busy reshaping the data-provision branch, strengthening the consultancy capabilities of the business and setting…

Pharma As Egypt continues to grapple with the proliferation of the hepatitis C virus, fresh treatment, prevention and market access pathways are now being applied. Given the severity of Egypt’s hepatitis C epidemic, the national campaign against viral hepatitis remains Egypt’s top healthcare priority. According to Roche’s regional general manager, Ehab…

Pharma Concerted efforts are, at last, being made to redraw the rulebook and tidy up a local regulatory landscape long renowned for its torpor, dysfunction and ineffectuality. The Egyptian pharmaceutical market is currently regulated by the Ministry of Health itself, with all issues related to pharmaceuticals falling under the responsibility of…

Pharma Abramo Brandi, Octapharma Italy’s MD, discusses the challenges of the tender system in Italy and how he has grown the company year-on-year in the midst of a global economic crisis. What are some of your major achievements since becoming Managing Director of Octapharma Italy in 2008? I was asked to…